KZR is the ticker symbol for Kezar Life Sciences, Inc., a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks KZR with AI-powered analysis, a 32-signal quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is KZR a good stock to buy?

KZR is tracked on 13F Pro with SEC EDGAR data, but is not currently included in our 32-signal AI quality ranking. The full company profile with financials and AI insights is at https://13fpro.ai/company/KZR.

Where does 13F Pro source KZR data?

All Kezar Life Sciences, Inc. fundamentals and ownership data come directly from SEC EDGAR. Kezar Life Sciences, Inc. files with the SEC under CIK 1645666. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

Kezar Life Sciences, Inc.(KZR)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-03-31.

Kezar Life Sciences, Inc. (KZR) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. KZR is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 46 institutional filers currently hold this stock. Based on the latest XBRL financial filings (Q1 2026), Kezar Life Sciences, Inc. reports net income of $-5.8M, free cash flow of $-7.4M. Top institutional holders of KZR by reported 13-F value include BML Capital Management, SUVRETTA CAPITAL MANAGEMENT, TANG CAPITAL MANAGEMENT, based on the most recent SEC filings. KZR trades on the Nasdaq exchange and files with the SEC under CIK 1645666. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KZR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Kezar Life Sciences, Inc. directly from SEC EDGAR.

Net Income

$-5.8M

Free Cash Flow

$-7.4M

KZR key financials by period

Kezar Life Sciences, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Operating margin
FY 2023	10-K	$7.0M	$-101.9M	—

Institutions holding KZR

Institutional investors reporting a position in Kezar Life Sciences, Inc. on SEC Form 13F.
Institution	Shares	Value	Reported
BML Capital Management	720,787	$5.3M	2026-03-31
SUVRETTA CAPITAL MANAGEMENT	716,759	$5.3M	2026-03-31
TANG CAPITAL MANAGEMENT	664,314	$4.9M	2026-03-31
VANGUARD CAPITAL MANAGEMENT	290,529	$2.2M	2026-03-31
Rangeley Capital	243,073	$1.8M	2026-03-31
Affinity Asset Advisors	229,076	$1.7M	2026-03-31
RENAISSANCE TECHNOLOGIES	188,426	$1.4M	2026-03-31
SUSQUEHANNA INTERNATIONAL GROUP, LLP	149,800	$1.1M	2026-03-31
MILLENNIUM MANAGEMENT	142,050	$1.1M	2026-03-31
Peapod Lane Capital	126,692	$924.5K	2026-03-31

SEC EDGAR: CIK 1645666 →

Kezar Life Sciences, Inc.

KZR

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Limited institutional coverage

Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 46 institutional filers currently hold this stock.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.